Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.79 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.12 +11.2% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.79 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.12 +11.2% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

By The Northwire Desk — AI Analysis May 26, 2026 · 07:30 BCT · 4.87 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • The most recent release (May 26, 2026) confirms the Data Safety Monitoring Board (DSMB) issued its sixth consecutive positive recommendation for the Phase 3 Bria-ABC study in metastatic breast cancer.
  • No safety concerns were identified regarding Bria-IMT plus immune checkpoint inhibitor (CPI); the study continues without modifications under FDA Fast Track designation.
  • Historical progression shows consistent DSMB approvals: October 2025 (4th), February 2026 (5th), and May 2026 (6th).
  • Concurrent pipeline updates include expansion into ovarian cancer (Bria-OVA+) and prostate cancer (Bria-PROS+), with Bria-BRES+ receiving FDA IND clearance.
  • Enrollment milestones indicate >230 patients screened and >230 enrolled as of May 12, 2026, exceeding previous expectations from late 2025.
  • ASCO 2026 presentations (May 22) highlighted Phase 2 survival data (median OS 16.6 months) and quality of life preservation in heavily pre-treated patients.
Material Impact
  • The DSMB safety confirmation is a routine quarterly milestone for a pivotal Phase 3 trial under FDA oversight; it validates the current trajectory but does not alter efficacy expectations.
  • Market reaction appears muted relative to historical volatility, evidenced by the stock trading near 52-week lows ($4.87) despite positive clinical data and financing.
  • The news is incremental rather than transformative; safety is a prerequisite for approval, not a guarantee of commercial success or valuation expansion.
  • Previous financing (January 2026) diluted shareholders significantly, creating resistance levels that the current price has yet to overcome.
  • No new strategic investors were disclosed in this release, limiting immediate capital confidence signals compared to prior "Game Changer" criteria.
BCT · Price
Company Overview
  • Flagship Project: Bria-IMT (Bria-ABC Phase 3 study) for metastatic breast cancer in combination with immune checkpoint inhibitors.
  • Regulatory Status: FDA Fast Track Designation granted to the combination regimen.
  • Primary Endpoint: Overall Survival (OS); Interim analysis triggered after 144 patient deaths.
  • Secondary Pipeline: Bria-BRES+ (Breast), Bria-PROS+ (Prostate), Bria-OVA+ (Ovarian) utilizing the Bria-OTS+ platform.
  • Clinical Sites: Expanded to over 79 sites across 23 U.S. states, including major academic centers like Penn Medicine and NYU Langone.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 22, 2026 · 07:30

ASCO Data Confirms Survival Benefit Amidst Dilution Headwinds

Other